Aura Biosciences, Inc.
AURA
$5.36
-$0.04-0.74%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.81M | 21.84M | 20.71M | 19.98M | 19.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.11M | 93.09M | 90.35M | 87.86M | 84.99M |
| Operating Income | -96.11M | -93.09M | -90.35M | -87.86M | -84.99M |
| Income Before Tax | -86.81M | -82.99M | -80.50M | -78.47M | -76.27M |
| Income Tax Expenses | 113.00K | 226.00K | 183.00K | 183.00K | 137.00K |
| Earnings from Continuing Operations | -86.92 | -83.22 | -80.69 | -78.65 | -76.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.92M | -83.22M | -80.69M | -78.65M | -76.41M |
| EBIT | -96.11M | -93.09M | -90.35M | -87.86M | -84.99M |
| EBITDA | -94.89M | -91.83M | -89.06M | -86.59M | -83.70M |
| EPS Basic | -1.75 | -1.73 | -1.79 | -1.86 | -1.93 |
| Normalized Basic EPS | -1.09 | -1.08 | -1.12 | -1.16 | -1.20 |
| EPS Diluted | -1.75 | -1.73 | -1.79 | -1.86 | -1.93 |
| Normalized Diluted EPS | -1.09 | -1.08 | -1.12 | -1.16 | -1.20 |
| Average Basic Shares Outstanding | 198.60M | 193.31M | 181.84M | 170.14M | 158.48M |
| Average Diluted Shares Outstanding | 198.60M | 193.31M | 181.84M | 170.14M | 158.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |